Sökning: id:"swepub:oai:gup.ub.gu.se/82200" >
Safe administration...
Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
-
- Mellgren, Karin, 1962 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
- Nilsson, C (författare)
- Karolinska Institutet
-
- Fasth, Anders, 1945 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
visa fler...
-
- Abrahamsson, Jonas, 1954 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
- Winiarski, J (författare)
- Karolinska Institutet
-
- Ringdén, O (författare)
- Karolinska Institutet
-
- Hassan, M (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2007-12-17
- 2008
- Engelska.
-
Ingår i: Bone marrow transplantation. - : Springer Science and Business Media LLC. - 0268-3369 .- 1476-5365. ; 41:7, s. 621-5
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- We compared outcome and toxicity in two paediatric groups undergoing SCT and treated with busulphan (BU) by the oral route of administration. One group receiving the standard dose of 1 mg/kg q.i.d. for a total of 16 doses was compared with age- and disease-matched patients receiving 2 mg/kg of BU b.i.d. for a total of eight doses. Seventy-two patients from two Swedish paediatric transplantation centres were included; one centre used a standard q.i.d. administration (n=37) and the second centre used a b.i.d. administration setting (n=35). Our primary objective was to determine the incidence of veno-occlusive disease (VOD), graft-versus-host disease (GVHD), relapse frequency and transplant-related mortality in both cohorts. A total of 17 autologous and 55 allogeneic transplantations was performed for malignant (n=47) and non-malignant (n=25) diseases in the two centres during the period 1990-2005. No significant difference in the incidence of VOD, graft rejection, GVHD, relapse rate or overall survival was observed between the two centres. The clinical outcome of SCT for paediatric patients conditioned with oral BU at a dose of 2 mg/kg for eight doses is comparable to that found for children conditioned using the standard regimen given 1 mg/kg q.i.d. for 16 doses.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
Nyckelord
- Administration
- Oral
- Busulfan
- administration & dosage
- adverse effects
- Child
- Child
- Preschool
- Dose-Response Relationship
- Drug
- Female
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- methods
- Hepatic Veno-Occlusive Disease
- Humans
- Infant
- Leukemia
- therapy
- Male
- Myeloablative Agonists
- administration & dosage
- adverse effects
- Survival Analysis
- Transplantation Conditioning
- methods
- Transplantation
- Autologous
- Transplantation
- Homologous
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas